Taxotere Will Benefit From “Average Sales Price” Reimbursement
Aventis expects Taxotere's performance in the U.S. to receive a boost from the implementation of "average sales price" reimbursement under Medicare in 2005
Aventis expects Taxotere's performance in the U.S. to receive a boost from the implementation of "average sales price" reimbursement under Medicare in 2005